When do weight loss injections start working — and what affects your timeline?

The first few weeks: what's actually happening in your body

When you take the first dose of a GLP-1 or dual GIP/GLP-1 medicine, it begins binding to hormone receptors involved in appetite regulation and gastric emptying almost straight away. Many people describe a quietening of the background hunger that had previously felt constant, the medical term is a reduction in appetite signalling, but patients often put it more plainly: food simply becomes less urgent.

That said, the starter dose is deliberately modest. Tirzepatide begins at 2.5 mg and semaglutide at 0.25 mg, not because those amounts drive significant fat loss, but because starting low gives your digestive system time to adjust and reduces the likelihood of nausea. Think of these early weeks as calibration. The tirzepatide prescribing schedule described in the Mounjaro SmPC typically increases every four weeks, meaning the dose with the strongest effect on weight may not be reached until month three or four.

On the scales, most people see little change in week one. A small drop in the first fortnight is common and partly reflects reduced food volume and water shifts rather than fat loss. Real fat-mass reduction accelerates as the therapeutic dose beds in. The NHS tirzepatide information page notes that weight loss is progressive and that treatment works best alongside a reduced-calorie diet and increased physical activity.

Months two and three: when the numbers usually start to move

The eight-to-twelve week window is when most patients and their prescribers start drawing conclusions. By this point, many people will have reached their second or third dose level, appetite suppression is more consistent, and the cumulative calorie deficit is large enough to show on the scales. It is also the period when the lifestyle component matters most, what you eat on treatment shapes how effectively each dose can work, and what you eat while on weight loss injections is worth thinking through carefully before you start.

SURMOUNT-1, the pivotal trial for tirzepatide, ran for 72 weeks and showed an average body-weight reduction of around 20–21% at the 15 mg dose. STEP 1, the equivalent trial for semaglutide 2.4 mg (Wegovy), ran 68 weeks and showed around 15% average reduction. These figures represent outcomes across thousands of participants, individual results ranged considerably either side. Citing them here is not to set a target for your own first month but to illustrate that the medicine was designed for a long arc, not a quick sprint.

If progress at month three feels slower than expected, that is worth raising with your prescriber rather than assuming the treatment is not working. There are practical and clinical reasons why early response varies, and adjusting the approach mid-treatment is exactly what the ongoing review process is for.

Why some people see results faster, and what you can do about the factors you control

Starting weight matters: people with a higher BMI at baseline often see larger absolute losses in the early months, though the percentage change tends to even out over time. Metabolic factors, including insulin sensitivity and how quickly gastric emptying slows, differ between individuals and affect how strongly the first doses land.

The controllable factors are diet and movement. Clinical evidence consistently shows that the medicines produce their best outcomes when used alongside a calorie-appropriate eating pattern and regular activity, not as an add-on but as a genuine part of the treatment. Keeping your pen stored correctly also matters for maintaining its effectiveness; most people find the fridge door the most reliable spot, though the exact storage window is set out in the Patient Information Leaflet and should be your guide.

Gastrointestinal side effects (nausea, loose stools, reflux) are common in the early weeks and can themselves reduce food intake, which some people mistake for the appetite effect. The two overlap but are not the same. Nausea usually eases as your body adapts; persistent or severe symptoms are a reason to speak with your prescriber. If you reach the maximum tolerated dose and still feel the injections do not seem to be working, it is worth reading about why weight loss injections sometimes stop producing results, as there are structured ways to review what might be getting in the way.

What the evidence tells us about long-term timelines

Both tirzepatide and semaglutide are licensed in the UK for weight management (Mounjaro under NICE appraisal TA1026 and Wegovy under TA875) and the trial programmes that supported those approvals measured outcomes over more than a year for good reason. The medicines produce cumulative weight loss; the slope is steepest in the first six months and then continues more gradually. NICE's guidance on tirzepatide includes a review point at six months: if less than 5% weight loss has been achieved at the highest tolerated dose, continuing the medicine is reassessed.

That review point is a design feature, not a threat. It is the system doing what good clinical oversight should do. For a private patient at a service like ours at nume, the same principle applies: every repeat order is reviewed by a prescriber, not processed automatically. That clinical re-review is what separates a supervised course of treatment from simply refilling a pen.

If you are still weighing up which injection might suit your circumstances, it is worth reading about which weight loss injections tend to show results earliest. And when you are ready to discuss your own situation, checking your eligibility with our prescribers is the natural next step.